Prediction of pharmacokinetic / pharmacodynamic properties of aldosterone synthase inhibitors at
drug discovery stage using an artificial intelligence-physiologically based pharmacokinetic model.
Predicting pharmacodynamic effects through early drug discovery with artificial
intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling.
Accelerating Development of Benziamidazole-Class Proton Pump Inhibitors: A Mechanism-Based PK/PD
Model to Optimize Study Design with Ilaprazole as a Case Drug.